Prognostic Impact of Peak Aortic Jet Velocity in Conservatively Managed Patients With Severe Aortic Stenosis: An Observation From the CURRENT AS Registry by Nakatsuma, Kenji et al.
Title
Prognostic Impact of Peak Aortic Jet Velocity in
Conservatively Managed Patients With Severe Aortic Stenosis:
An Observation From the CURRENT AS Registry
Author(s)
Nakatsuma, Kenji; Taniguchi, Tomohiko; Morimoto, Takeshi;
Shiomi, Hiroki; Ando, Kenji; Kanamori, Norio; Murata,
Koichiro; Kitai, Takeshi; Kawase, Yuichi; Izumi, Chisato;
Miyake, Makoto; Mitsuoka, Hirokazu; Kato, Masashi; Hirano,
Yutaka; Matsuda, Shintaro; Inada, Tsukasa; Nagao, Kazuya;
Murakami, Tomoyuki; Takeuchi, Yasuyo; Yamane, Keiichiro;
Toyofuku, Mamoru; Ishii, Mitsuru; Minamino‐Muta, Eri;
Kato, Takao; Inoko, Moriaki; Ikeda, Tomoyuki; Komasa,
Akihiro; Ishii, Katsuhisa; Hotta, Kozo; Higashitani, Nobuya;
Kato, Yoshihiro; Inuzuka, Yasutaka; Maeda, Chiyo; Jinnai,
Toshikazu; Morikami, Yuko; Saito, Naritatsu; Minatoya, Kenji;
Kimura, Takeshi; the CURRENT AS Registry Investigators




© 2017 The Authors. Published on behalf of the American
Heart Association, Inc., by Wiley. This is an open access article
under the terms of the Creative Commons Attribution-
NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is
properly cited, the use is non-commercial and no modifications




Prognostic Impact of Peak Aortic Jet Velocity in Conservatively
Managed Patients With Severe Aortic Stenosis: An Observation From
the CURRENT AS Registry
Kenji Nakatsuma, MD; Tomohiko Taniguchi, MD; Takeshi Morimoto, MD, MPH; Hiroki Shiomi, MD; Kenji Ando, MD; Norio Kanamori, MD;
Koichiro Murata, MD; Takeshi Kitai, MD; Yuichi Kawase, MD; Chisato Izumi, MD; Makoto Miyake, MD; Hirokazu Mitsuoka, MD; Masashi
Kato, MD; Yutaka Hirano, MD; Shintaro Matsuda, MD; Tsukasa Inada, MD; Kazuya Nagao, MD; Tomoyuki Murakami, MD; Yasuyo Takeuchi,
MD; Keiichiro Yamane, MD; Mamoru Toyofuku, MD; Mitsuru Ishii, MD; Eri Minamino-Muta, MD; Takao Kato, MD; Moriaki Inoko, MD;
Tomoyuki Ikeda, MD; Akihiro Komasa, MD; Katsuhisa Ishii, MD; Kozo Hotta, MD; Nobuya Higashitani, MD; Yoshihiro Kato, MD; Yasutaka
Inuzuka, MD; Chiyo Maeda, MD; Toshikazu Jinnai, MD; Yuko Morikami, MD; Naritatsu Saito, MD; Kenji Minatoya, MD; Takeshi Kimura, MD;
on behalf of the CURRENT AS Registry Investigators*
Background-—There are limited data regarding the risk stratification based on peak aortic jet velocity (Vmax) in patients with
severe aortic stenosis (AS).
Methods and Results-—Among 3815 consecutive patients with severe AS enrolled in the CURRENT AS (Contemporary Outcomes
After Surgery and Medical Treatment in Patients With Severe Aortic Stenosis) registry, the study population consisted of 1075
conservatively managed patients with Vmax ≥4.0 m/s and left ventricular ejection fraction ≥50%. The study patients were
subdivided into 3 groups based on Vmax (group 1, 4.0 ≤ Vmax <4.5 m/s, N=550; group 2, 4.5 ≤ Vmax <5 m/s, N=279; and group
3, Vmax ≥5 m/s, N=246). Cumulative 5-year incidence of AS-related events (aortic valve–related death or heart failure
hospitalization) was incrementally higher with increasing Vmax (entire population; 38.0%, 49.4%, and 62.8%, P<0.001; symptomatic
patients; 55.7%, 60.9%, and 72.2%, P=0.008; and asymptomatic patients; 29.4%, 38.9%, and 47.7%, P=0.005). After adjusting for
confounders, the excess risk of group 2 and group 3 relative to group 1 for AS-related events remained significant (hazard ratio,
1.39; 95% CI, 1.07–1.81; P=0.02, and hazard ratio, 1.53; 95% CI, 1.17–2.00; P=0.002, respectively). The effect size of group 3
relative to group 1 for AS-related events in asymptomatic patients (N=479) was similar to that in symptomatic patients (N=596;
hazard ratio, 1.59; 95% CI, 1.01–2.52; P=0.047, and hazard ratio, 1.67; 95% CI, 1.16–2.40, P=0.008, respectively), and there was
no significant overall interaction between the symptomatic status and the effect of the Vmax categories on AS-related events
(interaction, P=0.88).
Conclusions-—In conservatively managed severe AS patients with preserved left ventricular ejection fraction, increasing Vmax was
associated with incrementally higher risk for AS-related events. However, the cumulative 5-year incidence of the AS-related events
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remained very high even in asymptomatic patients with less greater Vmax. ( J Am Heart Assoc. 2017;6:e005524. DOI:
10.1161/JAHA.117.005524.)
Key Words: aortic stenosis • clinical outcomes • peak aortic jet velocity
I n the current American and European guidelines for themanagement of severe aortic stenosis (AS), the presence
of AS-related symptoms is the only 1 class 1 recommendation
for aortic valve replacement (AVR) surgery.1,2 However, many
patients with severe AS who could potentially be benefited
from AVR may not complain any symptoms because of their
sedentary life style. Furthermore, it is often difficult to
distinguish the non-specific symptoms such as fatigue and
dyspnea on exertion from the true AS-related symptoms.
Several previous observational studies including our recent
report have suggested better long-term clinical outcomes with
initial AVR strategy as compared with conservative strategy in
asymptomatic patients with severe AS.3–5 Therefore, it is
increasingly important to identify some additional objective
parameters accurately predicting higher-risk patients with
severe AS other than AS-related symptoms. Myocardial
fibrosis detected by magnetic resonance imaging and novel
biomarkers for fibrosis or myocyte stress such as growth
differentiation factor 15 or soluble ST2 have emerged as
promising predictors of outcomes in patients with severe
AS.6–10 However, the diagnostic tests used in the decision
making for AVR should be readily and repeatedly available in
daily clinical practice. Therefore, among asymptomatic
patients with severe AS, the current guidelines recommend
AVR as the class 2a indication in patients with very severe AS
(peak aortic jet velocity [Vmax] ≥5.0 m/s or mean aortic
pressure gradient ≥60 mm Hg), or left ventricular dysfunction
(left ventricular ejection fraction [LVEF] <50%) as evaluated by
echocardiography.1,2 However, there are limited data regard-
ing risk stratification based on Vmax in patients with severe
AS, although Vmax as assessed by Doppler echocardiography
is considered to be a major predictor of adverse events in
patients with moderate or severe AS, leading to the definition
of severe AS as Vmax ≥4.0 m/s or mean aortic pressure
gradient ≥40 mm Hg.11–13 Previous single-center studies
have reported that asymptomatic severe AS patients with
Vmax ≥5.0 m/s are at higher risk for adverse events,4,14
whereas other studies reported that patients with Vmax
≥4.5 m/s are at higher risk for adverse events.5,15 The
appropriate cut-off value for Vmax predicting adverse out-
comes has not been yet established in severe AS patients
with Vmax ≥4.0 m/s. Therefore, we sought to evaluate the
prognostic impact of Vmax in conservatively managed severe
AS patients with preserved LVEF using data from a large
Japanese multicenter registry of patients with severe AS.
Methods
Study Population
The CURRENT AS (Contemporary Outcomes After Surgery and
Medical Treatment in Patients With Severe Aortic Stenosis)
registry is a retrospective, multicenter registry enrolling
consecutive patients with severe AS who were treated at 27
centers in Japan between January 2003 and December 2011.
Inclusion periods of the consecutive patients in each center
were different according to the accessibility for the hospital
chart in each center. The institutional review boards at all 27
participating centers (see Appendix) approved the protocol.
Written informed consent from each patient was waived in
this retrospective study, because we used clinical information
obtained in the routine clinical practice, and no patients
refused to participate in the study when contacted for
follow-up.
The design and patient enrollment of the CURRENT AS
registry have been described previously.3 Among the 3815
patients enrolled in the registry who met the definition of
severe AS (Vmax >4.0 m/s, mean aortic pressure gradient
>40 mm Hg, or aortic valve area <1.0 cm2) for the first time
during the study period, we excluded 1197 patients in whom
aortic valve replacement (AVR) was selected as the initial
treatment strategy after the index echocardiography, 5
Clinical Perspective
What Is New?
• The cumulative 5-year incidence of the aortic stenosis (AS)-
related events remained very high in asymptomatic patients
with less greater Vmax, and increasing peak aortic jet
velocity was associated with incrementally higher risk for
AS-related events in conservatively managed severe AS
patients with preserved left ventricular ejection fraction.
What Are the Clinical Implications?
• The initial aortic valve replacement strategy would be a
viable option in asymptomatic patients with severe AS with
peak aortic jet velocity 4.0 to 5.0 m/s, although definitive
conclusions cannot be drawn until the completion of the
ongoing trial comparing initial aortic valve replacement
strategy with conservative strategy in patients with asymp-
tomatic severe AS.
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patients whose Vmax values were unknown, 1427 patients
whose Vmax values were <4.0 m/s, and 111 patients whose
left ventricular ejection fraction (LVEF) was <50%. Therefore,
the current study population consisted of 1075 patients with
severe AS with Vmax ≥4.0 m/s and LVEF ≥50% who were
managed conservatively after the index echocardiography
(Figure 1). The study patients were subdivided into 3 groups
based on the Vmax values: group 1 (4.0 ≤ Vmax <4.5 m/s:
N=550); group 2 (4.5 ≤ Vmax <5 m/s: N=279); and group 3
(Vmax ≥5 m/s: N=246; Figure 1). We compared the baseline
characteristics and 5-year clinical outcomes among the 3
groups.
Data Collection and Definitions
The collection of the baseline clinical information was
conducted through hospital chart and database reviews.
Angina, syncope, and heart failure (HF) symptoms including
dyspnea were regarded as AS-related symptoms. All patients
at each participating center underwent comprehensive
2-dimensional and Doppler echocardiographic evaluations.
Vmax and mean aortic pressure gradient were calculated
using the simplified Bernoulli equation. Aortic valve area was
calculated using the standard continuity equation and
normalized to body surface area.16 Left ventricular (LV) mass
was measured with the formula recommended by the
American Society of Echocardiography, and was indexed to
body surface area as follows: LV mass=0.891.04
[(LVDd+LVPWTd+IVSTd)3(LVDd)3]+0.6, where LVDd is the
LV diastolic diameter, IVSTd is the diastolic interventricular
septal wall thickness, and LVPWTd is the diastolic LV
posterior wall thickness. According to the American Society
of Echocardiography recommendations, LV hypertrophy was
defined as an LV mass index >115 g/m2 in male patients and
>95 g/m2 in female patients.17
The follow-up data were mainly collected through a review
of hospital charts or through contact with patients, their
relatives, and/or the referring physicians asking questions on
survival status, symptoms, and subsequent hospitalization.
The primary outcome measure in the present analysis was
a composite of aortic valve–related death and HF hospital-
ization. Cause of death was classified according to the VARC
(Valve Academic Research Consortium) definitions and was
adjudicated by a clinical event committee (see Appendix).18,19
Sudden death was defined as unexplained death in previously
stable patients. Aortic valve–related death included aortic
procedure–related death, sudden death, and death attributed
to HF that was possibly related to the aortic valve. HF
Figure 1. Study flow chart. Treatment strategies (initial AVR or conservative) were selected shortly after
the index echocardiography. AS indicates aortic stenosis; AVR, aortic valve replacement; CURRENT AS,
Contemporary Outcomes After Surgery and Medical Treatment in Patients With Severe Aortic Stenosis; EF,
ejection fraction; Vmax, peak aortic jet velocity.
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Table 1. Baseline Characteristics
Group 1: 4.0 ≤ Vmax <4.5 Group 2: 4.5 ≤ Vmax <5.0 Group 3: Vmax ≥5.0
P Value(N=550) (N=279) (N=246)
Clinical characteristics
Age, y 78.59.5 79.59.9 81.89.6 <0.001
Age ≥80 y* 267 (49) 148 (53) 171 (70) <0.001
Male* 214 (39) 89 (32) 62 (25) <0.001
BMI <22 kg/m2* 328 (60) 194 (70) 189 (77) <0.001
BSA, m2 1.470.19 1.420.18 1.380.19 <0.001
Symptoms possibly related to AS 186 (34) 139 (50) 154 (63) <0.001
Acute heart failure* 79 (14) 53 (19) 71 (29) <0.001
Hypertension* 385 (70) 193 (69) 160 (65) 0.37
Current smoking* 37 (6.7) 13 (4.7) 12 (4.9) 0.38
Dyslipidemia 178 (32) 75 (27) 57 (23) 0.02
On statin therapy 122 (22) 61 (22) 38 (15) 0.08
Diabetes mellitus 120 (22) 45 (16) 22 (8.9) <0.001
On insulin therapy* 23 (4.2) 11 (3.9) 2 (0.8) 0.04
Past myocardial infarction* 27 (4.9) 10 (3.6) 7 (2.9) 0.35
Past PCI 58 (11) 22 (7.9) 9 (3.7) 0.005
Past CABG 18 (3.3) 8 (2.9) 3 (1.2) 0.25
Past open heart surgery 37 (6.7) 22 (7.9) 5 (2.0) 0.01
Past symptomatic stroke* 70 (13) 33 (12) 28 (12) 0.85
Atrial fibrillation or flutter* 108 (20) 50 (18) 45 (18) 0.81
Aortic/peripheral vascular disease* 33 (6.0) 11 (3.9) 10 (4.1) 0.32
Serum creatinine, mg/dL 0.9 (0.7–1.3) 0.9 (0.7–1.3) 0.9 (0.7–1.2) 0.70
Hemodialysis* 52 (9.5) 25 (9.0) 15 (6.1) 0.28
Anemia* 298 (54) 153 (55) 154 (63) 0.07
Liver cirrhosis (Child-Pugh B or C)* 6 (1.1) 3 (1.1) 5 (2.0) 0.56
Malignancy currently under treatment* 20 (3.6) 19 (6.8) 11 (4.5) 0.12
Chronic lung disease (moderate or severe)* 13 (2.4) 19 (6.8) 10 (4.1) 0.0008
Coronary artery disease 119 (22) 48 (17) 32 (13) 0.01
Logistic EuroSCORE, % 8.5 (5.5–14.4) 10.4 (5.5–16.1) 11.8 (7.9–17.2) <0.001
EuroSCORE II, % 2.6 (1.6–3.9) 3.1 (1.8–4.8) 3.6 (2.3–5.2) <0.001
STS score (PROM), % 3.6 (2.2–5.9) 4.4 (2.4–6.8) 4.3 (2.6–7.7) 0.003
Etiology of aortic stenosis 0.79
Degenerative 497 (90) 247 (89) 221 (90)
Congenital 27 (4.9) 17 (6.1) 15 (6.1)
Rheumatic 24 (3.9) 11 (3.6) 8 (3.0)
Infective endocarditis 0 (0) 1 (0.4) 0 (0)
Other 3 (0.6) 3 (1.1) 2 (0.8)
Echocardiographic variables
Vmax, m/s 4.20.1 4.70.1 5.50.4 <0.001
Peak aortic PG, mm Hg 715 895 12019 <0.001
Mean aortic PG, mm Hg 415 516 7114 <0.001
Continued
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hospitalization was defined as hospitalization attributed to
worsening HF that required intravenous drug therapy. During
collection of clinical outcomes, group categorization by Vmax
had not been notified to the investigators. Furthermore, a
clinical event committee also adjudicated the outcomes in a
blind fashion to the group categorization by Vmax.
Statistical Analysis
We present continuous variables as the meanSD or median
with interquartile range and categorical variables as numbers
and percentages. We compared continuous variables using 1-
way ANOVA or the Kruskal–Wallis test according to their
distributions. We analyzed categorical variables with the chi-
squared test. We used the Kaplan–Meier method to estimate
the cumulative incidences of clinical events and assessed
intergroup differences with the log-rank test. The outcomes of
group 2 and group 3 were compared with those of group 1 in
multivariable Cox proportional hazard models by using dummy
variables. Consistent with our previous report, we used the 19
clinically relevant risk-adjusting variables (age, male, body
mass index <22 kg/m2, acute HF, hypertension, current
smoking, diabetes mellitus on insulin therapy, past myocardial
infarction, past symptomatic stroke, atrial fibrillation or flutter,
aortic/peripheral vascular disease, hemodialysis, anemia,
liver cirrhosis, malignancy current under treatment, chronic
lung disease, LV mass ≥181 g, any combined valvulvar
disease, and tricuspid regurgitation pressure gradient
≥40 mm Hg) indicated in Table 1. With the exception of
age, continuous risk-adjusting variables were dichotomized
using clinically meaningful reference values or median values.
We treated age as a continuous variable in the Cox
proportional hazards models. The center was incorporated
as the stratification variable. The effects of group 2 and group
3 relative to group 1 on the clinical outcomes were expressed
as adjusted hazard ratios (HR) and their 95% CIs. We also
calculated overall P values of categorized Vmax. We also
performed a subgroup analysis based on the presence or
absence of the AS-related symptoms at baseline with formal
interaction analysis between the subgroup factor and the
effect of the Vmax categories on the primary outcome
measure. We conducted a sensitivity analysis in which
patients who had undergone AVR or transcatheter aortic
valve implantation (TAVI) during follow-up period were
censored on the day of AVR or TAVI. Furthermore, we
performed another sensitivity analysis of isolated severe
asymptomatic AS patients, excluding those patients who had
other moderate or severe valvular disease. The follow-up
duration was calculated by the median follow-up duration of
patients who were free from all-cause death. Statistical
Table 1. Continued
Group 1: 4.0 ≤ Vmax <4.5 Group 2: 4.5 ≤ Vmax <5.0 Group 3: Vmax ≥5.0
P Value(N=550) (N=279) (N=246)
AVA (equation of continuity), cm2 0.770.18 0.670.19 0.540.16 <0.001
AVA index, cm2/m2 0.530.12 0.470.12 0.390.10 <0.001
LV end-diastolic diameter, mm 457 446 447 0.18
LV end-systolic diameter, mm 286 285 286 0.75
LVEF, % 68.08.2 67.48.1 67.88.9 0.62
IVST in diastole, mm 112 122 132 <0.001
PWT in diastole, mm 112 122 122 <0.001
LV mass, g* 18257 18953 20558 <0.001
LV hypertrophy 313 (70) 175 (80) 178 (93) <0.001
Any combined valvular disease (moderate or severe)* 196 (36) 122 (44) 132 (54) <0.001
Moderate or severe AR 108 (20) 68 (24) 73 (30) 0.008
Moderate or severe MS 11 (2.0) 9 (3.2) 11 (4.5) 0.14
Moderate or severe MR 86 (16) 49 (18) 66 (27) <0.001
Moderate or severe TR 70 (13) 44 (16) 45 (18) 0.11
TR pressure gradient ≥40 mm Hg* 64 (12) 53 (19) 64 (26) <0.001
We present the categorical variables as number (%), and the continuous variables as meanSD, or median with interquartile range. AR indicates aortic regurgitation; AVA, aortic valve area;
BMI, body mass index; BSA, body surface area; CABG, coronary artery bypass grafting; IVST, interventricular septum thickness; LV, left ventricular; LVEF, left ventricular ejection fraction;
MR, mitral regurgitation; MS, mitral stenosis; PCI, percutaneous coronary intervention; PG, pressure gradient; PROM, predicted risk of mortality; PWT, posterior wall thickness; STS, Society
of Thoracic Surgeons; TR, tricuspid regurgitation; Vmax, peak aortic jet velocity.
*Risk-adjusting variables selected for the multivariable Cox proportional hazards models.
DOI: 10.1161/JAHA.117.005524 Journal of the American Heart Association 5
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analyses were conducted by a physician (K.N.) and a
statistician (T.M.) with use of JMP (version 10.0.2) or SAS
software (version 9.4; both SAS Institute Inc, Cary, NC). All of




With increasing Vmax from group 1 to group 3, the patients
became older and more often had female sex, smaller body mass
index, AS-related symptoms, and higher surgical risk scores,
whereas they less often had dyslipidemia, diabetes mellitus,
chronic lung disease, and coronary artery disease (Table 1).
Regarding the echocardiographic variables, patients with higher
Vmax more often had greater LV mass values, LV hypertrophy,
combined valvular disease, and higher tricuspid regurgitation
gradient. LVEF was comparable across the 3 groups (Table 1).
Clinical Outcomes
Median follow-up duration of the surviving patients was 1336
(interquartile range, 966–1817) days. Cumulative 5-year inci-
dence of surgical AVR or transcatheter aortic valve implantation
(TAVI) was not different among the 3 groups (Figure 2).
Cumulative 5-year incidence of the primary outcome measure
(aortic valve–related death or HF hospitalization) was incre-
mentally higher with increasing Vmax from group 1 to group 3
(38.0%, 49.4%, and 62.8%; P<0.001), although the event rate
even in group 1 remained very high (Figure 3; Table 2). After
adjusting for potential confounders, the excess risk of group 2
and group 3 relative to group 1 for the primary outcome
measure remained significant (HR, 1.39; 95% CI, 1.07–1.81;
P=0.02, and HR, 1.53; 95% CI, 1.17–2.00; P=0.002, respec-
tively; Table 3). Cumulative incidences of the secondary
outcome measures, including all-cause death, cardiovascular
death, aortic valve–related death, sudden death, and HF
hospitalization, among the 3 groups followed the same trend
as that for the primary outcome measure (Table 2; Figure 4).
After adjusting for confounders, the excess risks of group 3
relative to group 1 for the individual components of the primary
outcome measure (aortic valve–related death and HF hospital-
ization, respectively) remained significant, whereas the risks of
group 3 relative to group 1 for the other secondary outcome
measures and the risks of group 2 relative to group 1 for the
secondary outcome measures, except for all-cause death and
HF hospitalization, were not significant (Table 2).
Subgroup Analysis Based on the Presence or
Absence of AS-Related Symptoms
There were 479 patients with and 596 patients without AS-
related symptoms at baseline. In the subgroup of symp-
tomatic patients, the differences in baseline characteristics
Figure 2. Cumulative 5-year incidence for surgical AVR or TAVI.
Kaplan–Meier event curves for surgical AVR or TAVI among the 3
groups according to Vmax values. AVR indicates aortic valve
replacement; TAVI, transcatheter aortic valve implantation; Vmax,
peak aortic jet velocity.
Figure 3. Cumulative 5-year incidence for the primary outcome
measure. Kaplan–Meier event curves for the composite of aortic
valve–related death or heart failure hospitalization among the 3 groups
according to Vmax values. Vmax indicates peak aortic jet velocity.
DOI: 10.1161/JAHA.117.005524 Journal of the American Heart Association 6
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among the 3 groups categorized by the Vmax values were
generally consistent with those in the entire study population
(Table 3). In the subgroup of asymptomatic patients, baseline
characteristics were not so much different among the 3
groups categorized by the Vmax values, except for the higher
prevalence of women, and smaller body mass index, as well as
the lower prevalence of dyslipidemia, diabetes mellitus, and
chronic lung disease with increasing Vmax. Age and surgical
risk scores in asymptomatic patients were not significantly
different among the 3 groups (Table 3). In both subgroups
with and without symptoms at baseline, cumulative 5-year
incidence of the primary outcome measure was incrementally
higher with increasing Vmax (Figure 5; Tables 4 and 5). After
adjusting for confounders, the higher risk of group 3 relative
to group 1 for the primary outcome measure remained
significant, whereas the excess risk of group 2 relative to
group 1 for the primary outcome measure was no longer
significant in both subgroups (Figure 6; Tables 4 and 5). The
effect size of group 3 relative to group 1 for the primary
outcome measure in asymptomatic patients was similar to
that in symptomatic patients, and there was also no
significant overall interaction between the symptomatic status
at baseline and the effect of the Vmax categories on the
primary outcome measure (interaction, P=0.88).
Sensitivity Analysis
When patients who had undergone AVR or TAVI during follow-
up period were censored on the day of AVR or TAVI, an
incrementally higher risk for the composite of aortic













P ValueHR 95% CI HR 95% CI
Aortic valve–related death/HF hospitalization
Group 1 (4.0 ≤ Vmax <4.5) 162 (38.0%) 1 (reference) <0.001 1 (reference) 0.004
Group 2 (4.5 ≤ Vmax <5.0) 113 (49.4%) 1.52 1.19 to 1.93 <0.001 1.39 1.07 to 1.81 0.02
Group 3 (Vmax ≥5.0) 126 (62.8%) 2.16 1.71 to 2.72 <0.001 1.53 1.17 to 2.00 0.002
All-cause death
Group 1 226 (45.0%) 1 (reference) <0.001 1 (reference) 0.11
Group 2 135 (52.5%) 1.27 1.02 to 1.57 0.03 1.29 1.02 to 1.64 0.04
Group 3 138 (63.8%) 1.53 1.24 to 1.89 <0.001 1.13 0.89 to 1.43 0.33
Cardiovascular death
Group 1 152 (33.7%) 1 (reference) <0.001 1 (reference) 0.23
Group 2 82 (36.4%) 1.14 0.87 to 1.49 0.33 1.17 0.87 to 1.57 0.31
Group 3 106 (53.9%) 1.75 1.36 to 2.24 <0.001 1.27 0.96 to 1.68 0.10
Aortic valve–related death
Group 1 98 (23.6%) 1 (reference) <0.001 1 (reference) 0.04
Group 2 58 (25.6%) 1.25 0.90 to 1.73 0.18 1.26 0.88 to 1.81 0.21
Group 3 90 (48.8%) 2.30 1.73 to 3.07 <0.001 1.54 1.11 to 2.14 0.01
Sudden death
Group 1 32 (7.9%) 1 (reference) 0.051 N/A
Group 2 20 (9.0%) 1.30 0.73 to 2.25 0.36 N/A
Group 3 25 (14.5%) 1.91 1.13 to 3.23 0.02 N/A
HF hospitalization
Group 1 128 (31.5%) 1 (reference) <0.001 1 (reference) 0.03
Group 2 89 (42.6%) 1.52 1.16 to 1.99 0.003 1.37 1.01 to 1.85 0.04
Group 3 96 (54.6%) 2.11 1.61 to 2.74 <0.001 1.44 1.06 to 1.97 0.02
Number of patients with event was counted through the entire follow-up period, whereas the cumulative incidence was truncated at 5 years. Aortic valve–related death included aortic
procedure–related death, sudden death, and death attributed to heart failure. HF hospitalization was defined as hospitalization attributed to worsening HF requiring intravenous drug
therapy. HF indicates heart failure; HR, hazard ratio; N, number; N/A, not assessed; Vmax, peak aortic jet velocity.
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(N=186) (N=139) (N=154) (N=364) (N=140) (N=92)
Clinical characteristics
Age, y 81.18.9 82.69.1 84.37.4 0.003 77.20.5 76.40.8 77.61.0 0.62
Age ≥80 y* 109 (59) 93 (67) 126 (82) <0.001 158 (43) 55 (39) 45 (49) 0.35
Male* 61 (33) 28 (20) 36 (23) 0.02 153 (42) 61 (44) 26 (28) 0.04
BMI <22 kg/m2* 121 (65) 107 (77) 124 (81) 0.003 207 (57) 87 (62) 65 (71) 0.047
BSA, m2 1.440.19 1.360.17 1.330.18 <0.001 1.480.19 1.480.18 1.460.18 0.52
Acute heart failure* 79 (42) 53 (38) 71 (46) 0.39    
Hypertension* 133 (72) 104 (75) 106 (69) 0.52 252 (69) 89 (64) 54 (59) 0.12
Current smoking* 8 (4.3) 7 (5.0) 6 (3.9) 0.89 29 (8.0) 6 (4.3) 6 (6.5) 0.34
Dyslipidemia 53 (28) 34 (24) 44 (29) 0.66 125 (34) 41 (29) 13 (14) <0.001
On statin therapy 35 (19) 28 (20) 30 (19) 0.96 87 (24) 33 (24) 8 (8.7) 0.005
Diabetes mellitus 36 (19) 21 (15) 14 (9.1) 0.03 84 (23) 24 (17) 8 (8.7) 0.006
On insulin therapy* 4 (2.2) 4 (2.9) 1 (0.7) 0.35 19 (5.2) 7 (5.0) 1 (1.1) 0.22
Past myocardial
infarction*
10 (5.4) 4 (2.9) 4 (2.6) 0.33 17 (4.7) 6 (4.3) 3 (3.3) 0.84
Past PCI 17 (9.1) 6 (4.3) 5 (3.3) 0.05 41 (11) 16 (11) 4 (4.4) 0.13
Past CABG 9 (4.8) 4 (2.9) 2 (1.3) 0.17 9 (2.5) 4 (2.9) 1 (1.1) 0.66
Past open heart surgery 19 (10) 10 (7.2) 3 (2.0) 0.01 18 (5.0) 12 (8.6) 2 (2.2) 0.09
Past symptomatic stroke* 25 (13) 13 (9.4) 15 (9.7) 0.42 45 (12) 20 (14) 13 (14) 0.81
Atrial fibrillation or flutter* 44 (24) 30 (22) 38 (25) 0.82 64 (18) 20 (14) 7 (7.6) 0.06
Aortic/peripheral vascular
disease*
10 (5.4) 2 (1.4) 5 (3.3) 0.16 23 (6.3) 9 (6.4) 5 (5.4) 0.94
Serum creatinine, mg/dL 0.9 (0.7–1.5) 0.9 (0.7–1.4) 0.9 (0.7–1.2) 0.97 0.8 (0.7–1.1) 0.9 (0.7–1.1) 0.8 (0.6–1.0) 0.15
Hemodialysis* 14 (7.5) 11 (7.9) 6 (3.9) 0.29 38 (10) 14 (10) 9 (9.8) 0.98
Anemia* 118 (63) 90 (65) 109 (71) 0.33 180 (49) 63 (45) 45 (49) 0.66
Liver cirrhosis
(Child-Pugh B or C)*
4 (2.2) 3 (2.2) 5 (3.3) 0.77 2 (0.6) 0 (0) 0 (0) 0.53
Malignancy currently
under treatment*
5 (2.7) 8 (5.8) 4 (2.6) 0.25 15 (4.1) 11 (7.9) 7 (7.6) 0.17
Chronic lung disease
(moderate or severe)*
6 (3.2) 10 (7.2) 9 (5.8) 0.26 7 (1.9) 9 (6.4) 1 (1.1) 0.01
Coronary artery disease 47 (25) 22 (16) 19 (12) 0.006 72 (20) 26 (19) 13 (14) 0.46
Logistic EuroSCORE, % 11.8 (7.0–19.2) 12.5 (8.4–18.0) 13.7 (10.1–21.7) 0.02 7.9 (5.1–12.1) 7.2 (4.8–13.3) 8.7 (5.1–13.3) 0.73
EuroSCORE II, % 3.8 (2.4–6.0) 4.0 (2.7–5.8) 4.2 (3.1–6.7) 0.045 2.2 (1.4–3.2) 2.3 (1.3–3.7) 2.5 (1.4–3.5) 0.68
STS score (PROM), % 5.1 (2.8–8.4) 5.4 (3.6–9.2) 5.7 (3.4–9.7) 0.20 3.2 (2.0–5.0) 3.1 (1.8–5.1) 3.3 (1.8–4.3) 0.75
Etiology of aortic stenosis 0.16 0.28
Degenerative 172 (92) 131 (94) 143 (93) 325 (89) 116 (83) 78 (85)
Congenital 4 (2.2) 1 (0.7) 7 (4.6) 23 (6.3) 16 (11) 8 (8.7)
Rheumatic 10 (5.4) 7 (5.0) 3 (2.0) 13 (3.6) 4 (2.9) 5 (5.4)
Continued
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valve–related death or HF hospitalization with increasing
Vmax was similarly observed as in the main analysis (adjusted
HR for group 2 relative to group 1, 1.36; 95% CI, 1.03–1.82,
P=0.03, and adjusted HR for group 3 relative to group 1, 1.70;
95% CI, 1.28–2.24; P<0.001). Furthermore, when this analysis
was restricted to isolated severe asymptomatic AS patients,
the cumulative 5-year incidence of the primary outcome
measure was incrementally higher with increasing Vmax
(27.8%, 43.2%, and 48.5%; log-rank, P=0.02). After adjusting
for possible confounders, the excess risk of group 2 and
group 3 relative to group 1 for the primary outcome measure
was no longer significant in the isolated severe asymptomatic
severe AS patients (adjusted HR for group 2 relative to group
1, 1.27; 95% CI, 0.75–2.17; P=0.38, and adjusted HR for
group 3 relative to group 1, 1.32; 95% CI, 0.70–2.48; P=0.40).
However, the magnitude of the effect of increasing Vmax for
the primary outcome measure was not so much different from






















(N=186) (N=139) (N=154) (N=364) (N=140) (N=92)
Infective endocarditis 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.7) 0 (0)
Other 0 (0) 0 (0) 1 (0.7) 3 (0.8) 3 (2.1) 1 (1.1)
Echocardiographic variables
Vmax, m/s 4.20.1 4.70.1 5.50.4 <0.001 4.20.1 4.70.1 5.30.3 <0.001
Peak aortic PG, mm Hg 715 885 12421 <0.001 715 896 11513 <0.001
Mean aortic PG, mm Hg 415 517 7416 <0.001 415 526 6710 <0.001
AVA (equation of
continuity), cm2
0.730.19 0.630.17 0.500.14 <0.001 0.790.18 0.700.20 0.610.16 <0.001
AVA index, cm2/m2 0.510.12 0.460.11 0.380.10 <0.001 0.540.11 0.480.12 0.420.11 <0.001
LV end-diastolic
diameter, mm
467 446 446 0.06 456 456 447 0.88
LV end-systolic
diameter, mm
295 285 286 0.04 276 285 275 0.30
LVEF, % 65.78.6 67.09.2 66.59.1 0.38 69.27.8 67.86.9 69.98.1 0.08
IVST in diastole, mm 122 122 132 <0.001 112 122 132 <0.001
PWT in diastole, mm 112 122 122 <0.001 112 122 122 <0.001
LV mass, g* 19061 18549 20857 0.002 17855 19356 20158 <0.001




86 (46) 75 (54) 99 (64) 0.004 110 (30) 47 (34) 33 (36) 0.52
Moderate or
severe AR
44 (24) 38 (27) 50 (32) 0.19 64 (18) 30 (21) 23 (25) 0.23
Moderate or severe MS 4 (2.2) 8 (5.8) 7 (4.6) 0.23 7 (1.9) 1 (0.7) 4 (4.4) 0.15
Moderate or severe MR 51 (27) 37 (27) 58 (38) 0.06 35 (9.6) 12 (8.6) 8 (8.7) 0.92
Moderate or
severe TR
37 (19) 30 (22) 36 (23) 0.74 33 (9.1) 14 (10) 9 (9.8) 0.94
TR pressure gradient
≥40 mm Hg*
34 (18) 38 (27) 54 (35) 0.002 30 (8.2) 15 (11) 10 (11) 0.58
We presented the categorical variables as number (%), and the continuous variables as meanSD, or median with interquartile range. AR indicates aortic regurgitation; AVA, aortic valve
area; BMI, body mass index; BSA, body surface area; CABG, coronary artery bypass grafting; IVST, interventricular septum thickness; LV, left ventricular; LVEF, left ventricular ejection
fraction; MR, mitral regurgitation; MS, mitral stenosis; PCI, percutaneous coronary intervention; PG, pressure gradient; PROM, predicted risk of mortality; PWT, posterior wall thickness;
STS, Society of Thoracic Surgeons; TR, tricuspid regurgitation; Vmax, peak aortic jet velocity.
*Risk-adjusting variables selected for the multivariable Cox proportional hazards models.
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Figure 4. Cumulative 5-year incidence for the secondary outcome measures. Kaplan–Meier event curves for
(A) all-cause death, (B) cardiovascular death, (C) aortic valve-related death, (D) sudden death, and (E) HF
hospitalization among the 3 groups according to Vmax values. HF indicates heart failure; Vmax, peak aortic jet
velocity.
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Discussion
The main findings of the present study were the following: (1)
In conservatively managed severe AS (Vmax ≥4.0 m/s)
patients with preserved LVEF, increasing Vmax (4.5–5.0 m/
s and ≥5.0 m/s) was associated with incrementally higher
risk for the primary composite outcome measure of aortic
valve–related death or HF hospitalization; (2) however, the
cumulative 5-year incidence of the AS-related serious adverse
events remained very high even in asymptomatic patients with
Vmax 4.0 to 4.5 m/s.
There are several previous studies evaluating the relation
between Vmax and long-term clinical outcomes in patients
with severe AS (Vmax ≥4.0 or 4.5 m/s).4,5,14,15 Kang et al
reported that patients with Vmax ≥5.0 m/s were associated
with higher cardiac mortality in 197 asymptomatic patients
with very severe AS (Vmax ≥4.5 m/s).4 Kitai et al reported
that patients with very severe AS (Vmax ≥5.0 m/s, mean
pressure gradient ≥50 mm Hg, or aortic valve area <0.6 cm2)
were associated with higher mortality and higher valve-related
event (cardiac death/HF hospitalization) among 108 conser-
vatively managed patients with severe AS (Vmax ≥4.0 m/s,
mean PG ≥40 mm Hg, or aortic valve area <1.0 cm2).14
Pellikka et al reported that patients with very severe AS
(Vmax ≥4.5 m/s) were associated with higher risk for cardiac
death or AVR with a relative risk of 4.9 among 143
asymptomatic patients with severe AS (Vmax ≥4.0 m/s),5
whereas the same group of investigators later reported that
patients with very severe AS (Vmax ≥4.5 m/s) were associ-
ated with higher risk for cardiac death or AVR with an HR of
1.48 among 622 asymptomatic patients with severe AS
(Vmax ≥4.0 m/s).15 All these previous studies were single-
center studies from the high-quality centers, which might be
associated with some limitations in extrapolating the study
results into real clinical practice with differences in the quality
of echocardiographic examinations, manner of patient follow-
up, and operative mortality rate of AVR across centers.
Furthermore, mean age of the patients enrolled in these
studies ranged from 63 to 72 years, which would be much
younger than the age of patients encountered in the
contemporary clinical practice. In the present study evaluating
the largest ever number of patients with average age of
80 years from 27 centers, increasing Vmax, particularly Vmax
≥5.0 m/s, was clearly associated with worse long-term AS-
related outcomes, consistent with previous studies. Notably,
the effect size of Vmax ≥5.0 m/s relative to Vmax 4.0 to
4.5 m/s for aortic valve–related death or HF hospitalization in
asymptomatic patients was similar to that in symptomatic
patients, supporting the guidelines recommendation of AVR in
asymptomatic patients with very severe AS (Vmax ≥5.0 m/
Figure 5. Cumulative 5-year incidence for the primary outcome measure in the subgroup analysis.
Kaplan–Meier event curves for the composite of aortic valve–related death or heart failure hospitalization
among the 3 groups according to Vmax values (A) in symptomatic patients and (B) in asymptomatic
patients. AS indicates aortic stenosis; Vmax, peak aortic jet velocity.
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s).1,2 Otto et al reported that Vmax value was an independent
predictor of death or AVR among 123 asymptomatic moder-
ate-to-severe AS patients (Vmax ≥2.5 m/s).20 Also, Gerdts
et al reported that an association between increasing Vmax
value and incrementally higher risk for cardiovascular events
in mild-to-moderate asymptomatic AS patients (Vmax
≥2.5 m/s).21 Furthermore, Rosenhek et al reported that
patients with Vmax ≥5.5 m/s were associated with a higher
risk for cardiac death or indication for AVR among 116
asymptomatic isolated very severe AS patients (Vmax
≥5.0 m/s).22 However, it should be noted that the event
rate for aortic valve–related death or HF hospitalization in this
study remained very high even in asymptomatic patients with
Vmax 4.0 to 4.5 m/s. Too much emphasis on the Vmax
values in the decision making for AVR might expose the
patients to unacceptably high event risk within a few years.
Based on the results from several observational studies
suggesting better long-term clinical outcomes with initial AVR
strategy as compared with conservative strategy in asymp-
tomatic patients with severe AS,3–5 the initial AVR strategy
would be a viable option in asymptomatic patients with severe
AS with Vmax 4.0 to 5.0 m/s, although the definitive
conclusion could not be drawn until the completion of the
ongoing trial comparing initial AVR strategy with conservative
strategy in patients with asymptomatic severe AS.23
Limitations
The current study has several limitations. First, we should
take the measurement error of the echocardiographic Vmax













P ValueHR 95% CI HR 95% CI
Aortic valve–related death/HF hospitalization
Group 1 (4.0 ≤ Vmax <4.5) 80 (55.7%) 1 (reference) 0.009 1 (reference) 0.02
Group 2 (4.5 ≤ Vmax <5.0) 68 (60.9%) 1.52 1.19 to 1.93 <0.001 1.31 0.89 to 1.92 0.18
Group 3 (Vmax ≥5.0) 91 (72.2%) 2.16 1.71 to 2.72 <0.001 1.67 1.16 to 2.40 0.006
All-cause death
Group 1 102 (55.8%) 1 (reference) 0.32 1 (reference) 0.33
Group 2 77 (60.3%) 1.1 0.82 to 1.48 0.53 1.31 0.92 to 1.86 0.14
Group 3 96 (69.3%) 1.24 0.94 to 1.64 0.13 1.17 0.84 to 1.63 0.37
Cardiovascular death
Group 1 75 (45.6%) 1 (reference) 0.06 1 (reference) 0.71
Group 2 46 (40.8%) 0.88 0.61 to 1.27 0.50 1.02 0.65 to 1.54 0.99
Group 3 76 (58.4%) 1.33 0.97 to 1.83 0.08 1.16 0.79 to 1.70 0.46
Aortic valve–related death
Group 1 51 (34.0%) 1 (reference) 0.002 1 (reference) 0.16
Group 2 33 (28.4%) 0.93 0.60 to 1.44 0.76 1.13 0.68 to 1.87 0.65
Group 3 67 (54.9%) 1.73 1.20 to 2.49 0.003 1.51 0.98 to 2.34 0.06
Sudden death
Group 1 14 (10.3%) 1 (reference) 0.48 N/A
Group 2 12 (10.8%) 1.21 0.55 to 2.62 0.63 N/A
Group 3 17 (17.9%) 1.54 0.76 to 3.19 0.23 N/A
HF hospitalization
Group 1 65 (50.4%) 1 (reference) 0.051 1 (reference) 0.12
Group 2 56 (56.8%) 1.31 0.91 to 1.87 0.14 1.36 0.89 to 2.10 0.16
Group 3 69 (64.4%) 1.52 1.08 to 2.14 0.02 1.52 1.01 to 2.30 0.045
Number of patients with event was counted through the entire follow-up period, whereas the cumulative incidence was truncated at 5 years. Aortic valve–related death included aortic
procedure-related death, sudden death, and death attributed to HF. HF hospitalization was defined as hospitalization attributed to worsening HF requiring intravenous drug therapy. HF
indicates heart failure; HR, hazard ratio; N, number; N/A, not assessed; Vmax, peak aortic jet velocity.
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into account in this study and also in the daily clinical
practice. Furthermore, the echocardiographic measurement
was not performed in a core laboratory, but in each
participating center. Therefore, we could not deny the
possibility for variations in the echocardiographic measure-
ment of Vmax. However, cardiologists and ultrasonographers
in each participating center had enough experience of
echocardiography, and the measurements were performed
according to the current guidelines.16 Second, patients with
greater Vmax were more likely to undergo AVR. Therefore, we
should assume the presence of selection bias among the
groups categorized by Vmax, because the conservatively
managed patients with greater Vmax might include higher
proportion of sicker patients unsuitable for AVR. However, we
chose the AS-related outcomes (aortic valve–related death or
HF hospitalization) as the primary outcome measure, which
would be less likely to be influenced by selection bias than all-
cause death. Third, we did not have data on the place where
patients were regularly followed during the study period and
whether the patients were included in any follow-up programs
or not. However, in 85% of patients, final follow-up
information was obtained from the hospital chart in the study
participating center, suggesting that the majority of patients
were followed by the cardiologists in the study participating
center. Finally, the presence of AS-related symptoms is a
class 1 indication of AVR. Therefore, risk stratification by
Vmax in symptomatic patients may not be necessary.
However, in the real clinical practice, patients sometimes
refuse AVR despite the presence of symptoms. Also, it is
sometimes difficult to make unequivocal diagnosis of AS-













P ValueHR 95% CI HR 95% CI
Aortic valve–related death/HF hospitalization
Group 1 (4.0 ≤ Vmax <4.5) 82 (29.4%) 1 (reference) 0.006 1 (reference) 0.11
Group 2 (4.5 ≤ Vmax <5.0) 45 (38.9%) 1.42 0.98 to 2.03 0.06 1.31 0.86 to 1.99 0.20
Group 3 (Vmax ≥5.0) 35 (47.7%) 1.86 1.23 to 2.73 0.004 1.59 1.01 to 2.52 0.047
All-cause death
Group 1 124 (39.4%) 1 (reference) 0.17 1 (reference) 0.24
Group 2 58 (45.4%) 1.21 0.88 to 1.65 0.23 1.34 0.94 to 1.92 0.11
Group 3 42 (54.0%) 1.36 0.95 to 1.91 0.10 1.23 0.83 to 1.82 0.31
Cardiovascular death
Group 1 77 (27.5%) 1 (reference) 0.11 1 (reference) 0.31
Group 2 36 (32.0%) 1.21 0.81 to 1.78 0.35 1.27 0.79 to 2.03 0.33
Group 3 30 (45.5%) 1.56 1.01 to 2.36 0.045 1.43 0.88 to 2.33 0.15
Aortic valve–related death
Group 1 47 (18.4%) 1 (reference) 0.03 1 (reference) 0.18
Group 2 25 (22.3%) 1.38 0.84 to 2.22 0.20 1.46 0.81 to 2.62 0.21
Group 3 23 (38.1%) 1.95 1.16 to 3.18 0.001 1.69 0.94 to 3.07 0.08
Sudden death
Group 1 18 (6.9%) 1 (reference) 0.42 N/A
Group 2 8 (7.5%) 1.15 0.47 to 2.56 0.74 N/A
Group 3 8 (10.2%) 1.76 0.72 to 3.91 0.20 N/A
HF hospitalization
Group 1 63 (22.8%) 1 (reference) 0.02 1 (reference) 0.18
Group 2 33 (30.3%) 1.35 0.87 to 2.04 0.17 1.19 0.73 to 1.94 0.50
Group 3 27 (41.0%) 1.87 1.17 to 2.91 0.009 1.65 0.97 to 2.83 0.07
Number of patients with event was counted through the entire follow-up period, whereas the cumulative incidence was truncated at 5 years. Aortic valve–related death included aortic
procedure-related death, sudden death, and death attributed to HF. HF hospitalization was defined as hospitalization attributed to worsening heart failure requiring intravenous drug
therapy. HF indicates heart failure; HR, hazard ratio; N, number; N/A, not assessed; Vmax, peak aortic jet velocity.
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related symptoms. Therefore, we did not exclude the symp-
tomatic patients, but rather conducted a stratified analysis
based on the presence or absence of symptoms.
Conclusions
In conservatively managed severe AS patients with preserved
LVEF, increasing Vmax was associated with incrementally
higher risk for the composite of aortic valve–related death or
HF hospitalization. However, the cumulative 5-year incidence
of the AS-related serious adverse events remained very high
even in asymptomatic patients with less greater Vmax.
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Figure 6. Unadjusted and adjusted effects of increasing Vmax on the primary outcome measure in the entire study population and in the
subgroups based on symptomatic status at baseline. Unadjusted and adjusted effects of group 2 (4.5 ≤ Vmax <5.0 m/s) and group 3 (Vmax
≥5.0 m/s) relative to group 1 (reference: 4.0 ≤ Vmax <4.5 m/s) on the composite of aortic valve–related death or heart failure hospitalization
were analyzed in the entire study population as well as in symptomatic and asymptomatic patients. There was no significant overall interaction
between symptomatic status and effect of Vmax categories (interaction, P=0.88). AS indicates aortic stenosis; HR, hazard ratio; N, number;
Vmax, peak aortic jet velocity.
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